RSV Prevention, Part III: Older Adult Vaccination
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.
RSV Prevention, Part II: Pediatric Vaccines and Maternal immunization
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
RSV Prevention, Part II: Pediatric Vaccines and Maternal immunization
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
Patient-Centered Value Frameworks
Avalere experts will discuss patient-centric value frameworks, their utility to different stakeholders, and how they can drive the transformation to a patient-centered, equitable health system at the AMCP Nexus 2022 conference.
RSV Prevention, Part I: Pediatric Monoclonal Antibodies
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
RSV Prevention, Part I: Pediatric Monoclonal Antibodies
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
NCDs, Part III: Agency Mandates, Decisions, Coverage and Access
Tune into the third episode in the Avalere Health Essential Voice podcast series focused on Agency decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs) by considering how potential policy and market catalysts 3 to 5 years out may help stakeholders think through opportunities and risks at key decision points ranging from early in development to implications for Part D.
NCDs, Part III: Agency Mandates, Decisions, Coverage and Access
Tune into the third episode in the Avalere Health Essential Voice podcast series focused on Agency decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs) by considering how potential policy and market catalysts 3 to 5 years out may help stakeholders think through opportunities and risks at key decision points ranging from early in development to implications for Part D.
Preparing for Legislative Change and Connecting Equity and Outcomes
Join us for a live, expert discussion on life sciences industry trends to watch in Q4.
Medicare Advantage, Part III: Performance Measures and STAR Ratings
Tune into the third episode in our video series focused on Medicare Advantage. In this segment, Avalere quality measures experts, Michael Lutz and Taylor Musser, discuss the shift toward member-reported measures and implications of recent measure reporting methodology updates.
Medicare Advantage, Part II: Influencing CMS Policy
Tune into the second episode in our video series focused on Medicare Advantage. In this segment, Avalere experts and former Center for Medicaid and Medicare (CMS) employees Sean Creighton and Tom Kornfield discuss their thoughts on the best ways for health plans to influence CMS decision making, including timing of engagement and critical messaging elements.
Medicare Advantage, Part I: The Future of MA
Tune into the first episode in our video series focused on Medicare Advantage. In this segment, Avalere experts and former Centers for Medicare & Medicaid Services (CMS) employees, Sean Creighton and Tom Kornfield, discuss the outlook for Medicare Advantage, factors that will influence growth of the program, and a behind-the-scenes look at CMS policymaking considerations.
NCDs, Part II: Evidence Development to Fulfill CED Requirements
Tune into the second episode in the Avalere Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS’s evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.
NCDs, Part I: Overview of NCDs, CED, and Potential Access Barriers
Tune into the first episode in the Avalere Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.
NCDs, Part I: Overview of NCDs, CED, and Potential Access Barriers
Tune into the first episode in the Avalere Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.
The Evolving Cell & Gene Therapy Market
Join Avalere’s panel of market access and policy experts for a discussion on the growing cell and gene therapy (CGT) pipeline, an in-depth look at the unique opportunities and challenges these novel therapies present, and an overview of the many hurdles stakeholders need to navigate for success.
Exploring the Kidney Care Environment, Part III: Addressing Healthcare Disparities
Tune into the third episode in the Avalere Health Essential Voice podcast miniseries focused on the evolving kidney care landscape. In the final segment, our Market Access and Policy experts take a deeper dive into disparities in kidney care and discuss how various groups are looking to address these gaps.
Exploring the Kidney Care Environment, Part III: Addressing Healthcare Disparities
Tune into the third episode in the Avalere Health Essential Voice podcast miniseries focused on the evolving kidney care landscape. In the final segment, our Market Access and Policy experts take a deeper dive into disparities in kidney care and discuss how various groups are looking to address these gaps.
Navigating Value-Based Care, Defining Value, and Drug Pricing Policy
Join Avalere for a live discussion on key trends in drug pricing, value, and regulatory shifts, and how these trends will impact manufacturers.
CMS Final Rate Announcement: How Should Plans Prepare?
Join Avalere’s healthcare policy experts for an analysis of the final rate announcement and a discussion on the future of Medicare Advantage (MA) and potential outcomes for health plans.